SLC11A2 Antibody

What are the primary applications for SLC11A2 antibodies in research?

SLC11A2 antibodies are validated for multiple research applications including:

• Western blot (WB) analysis

• Immunohistochemistry on paraffin sections (IHC-P)

• Immunohistochemistry on frozen sections (IHC-fr)

• Flow cytometry (FCM)

• ELISA

The selection of application depends on your experimental goals. For protein expression quantification, Western blot is commonly used, while tissue localization studies typically employ IHC techniques. Most commercial antibodies specify recommended applications in their technical documentation .

How do I select the appropriate SLC11A2 antibody for my experiment?

Selection criteria should include:

• Species reactivity: Ensure the antibody recognizes SLC11A2 in your species of interest. Available antibodies may react with human, mouse, rat, bovine, or other species .

• Isoform specificity: Determine whether you need to detect all four isoforms or specific variants of SLC11A2. Some antibodies are specific to all isoforms, while others target particular regions .

• Application compatibility: Verify the antibody is validated for your intended application.

• Epitope location: Consider whether N-terminal or C-terminal targeting is more appropriate for your research question .

• Clonality: Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies may provide higher sensitivity but potentially more background .

What positive control samples are recommended for SLC11A2 antibody validation?

Based on research data, recommended positive controls include:

• Cell lines: 293T, BxPC-3, SH-SY5Y, COLO 320 cells

• Tissue samples: Rat testis, rat kidney, intestinal mucosal samples

When validating a new SLC11A2 antibody, these samples have shown reliable expression levels of the protein and can serve as appropriate positive controls .

What are the optimal protocols for SLC11A2 detection by Western blot?

For optimal Western blot detection of SLC11A2:

• Sample preparation:

  • For intestinal samples: Scrape mucosal tissue with a razor blade after washing with physiological saline solution (PSS)

  • Place samples directly into Laemmli buffer and shear with a 25-gauge needle

  • Heat intestinal samples at 95°C for 6 minutes

  • For other tissues, heat samples in Laemmli buffer at 60°C for 15 minutes

• Working concentration:

  • Typical dilutions range from 1:500 to 1:2000 for Western blot

  • Recommended starting concentration: 1.25 μg/ml for SLC11A2 antibody

• Deglycosylation:

  • Consider treating samples with PNGase F to remove glycosylations

  • This can convert ~100 kDa bands to lower ~50 kDa bands, improving detection specificity

• Expected molecular weight:

  • Calculated MW: 61-62 kDa

  • Observed MW: 72 kDa (glycosylated form)

What are the recommended protocols for immunohistochemical detection of SLC11A2?

For optimal IHC results:

• Fixation and preparation:

  • Use 10% phosphate-buffered formalin fixation

  • Paraffin embedding is suitable for most applications

• Antibody concentration:

  • Working concentration: 5-15 μg/ml for IHC-P

  • Recommended dilution ranges from 1:50 to 1:200 for most antibodies

• Controls:

  • Always include negative controls (sections treated without primary antibody)

  • Use known positive tissues (intestinal epithelium, kidney) as reference

• Quantitation:

  • Perform quantitation using established protocols for consistency

  • Consider using digital image analysis for objective assessment

• Visualization:

  • Both chromogenic and fluorescent detection methods are suitable

  • For co-localization studies, immunofluorescence with compatible secondary antibodies is recommended

How can I distinguish between different SLC11A2 isoforms in my experiments?

SLC11A2 exists in four major isoforms that differ in their N-terminal and C-terminal sequences. To differentiate between isoforms:

• Antibody selection:

  • Use isoform-specific antibodies targeting unique regions

  • Some antibodies can recognize all four isoforms (check specificity in product documentation)

• RT-PCR approach:

  • Design primers specific to isoform-unique regions

  • Example primer sequences from research:

    • GAPDH (control): F-5′-AACTTTGGCATTGTGGAAGG-3′, R-5′-CACATTGGGGGTAGGAACAC-3′

    • rSLC11A2: F-5′-TGCTTGGTGGCCTAAAACTC-3′, R-5′-CCCCTGACAAAACCAGTCAT-3′

• Protein analysis:

  • Use higher resolution gels (10-12%) for better separation

  • Deglycosylation treatment with PNGase F can help distinguish isoforms

  • Expected molecular weights may vary between isoforms (50-100 kDa range)

• Expression patterns:

  • Isoform 1: Highly expressed in brain

  • Isoform 2: Highly expressed in spleen, thymus, and pancreas

  • Isoforms 3 and 4: Abundantly expressed in duodenum and kidney

What approaches are recommended for studying SLC11A2 in the context of iron metabolism disorders?

For studying SLC11A2 in iron metabolism disorders:

• Animal models:

  • Microcytic anemia (mk) mice and Belgrade (b) rats with G185R mutation in SLC11A2

  • Systemic SLC11A2 knockout models display more severe phenotypes than G185R mutants

• Human samples:

  • Patient samples with SLC11A2 mutations show marked anemia and hepatic iron overload

  • Compare with appropriate controls to establish baseline expression

• Functional studies:

  • Measure cellular iron uptake in transfected cells

  • Example: Transfection with SLC11A2 expression vector doubled cellular iron concentration (1.00 μg Fe/10^6 cells vs. 0.52 μg Fe/10^6 cells in controls)

• Localization studies:

  • Examine protein localization (plasma membrane vs. cytoplasmic)

  • Investigate trafficking under different iron conditions

• Protein-protein interactions:

  • Investigate interactions with iron regulatory proteins

  • Study co-localization with other transporters involved in iron homeostasis

How do post-translational modifications affect SLC11A2 antibody recognition?

Post-translational modifications significantly impact SLC11A2 antibody recognition:

• Glycosylation effects:

  • SLC11A2 is heavily glycosylated, appearing as ~100 kDa bands on Western blots

  • Deglycosylation with PNGase F reduces the apparent molecular weight to ~50 kDa

  • This modification can mask epitopes and affect antibody binding

• Experimental considerations:

  • For complete detection, consider running both native and deglycosylated samples

  • Sample preparation temperatures affect glycoprotein integrity (60°C for non-intestinal tissues, 95°C for intestinal samples)

• Antibody selection strategy:

  • Choose antibodies raised against peptide regions less affected by glycosylation

  • C-terminal antibodies may be less affected by N-terminal glycosylation patterns

• Membrane preparation protocol:

  • For membrane proteins like SLC11A2, specialized extraction buffers may be needed

  • Consider detergent-based extraction methods optimized for membrane glycoproteins

What are the optimal protocols for detecting SLC11A2 in brain tissue samples?

Brain tissue requires special considerations for SLC11A2 detection:

• Fixation protocols:

  • Fresh frozen sections are preferred for maintaining antigen integrity

  • If using fixed tissue, short fixation times (4-24 hours) with 4% paraformaldehyde are recommended

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Enzymatic retrieval methods may damage delicate brain tissue structure

• Background reduction:

  • Include additional blocking steps to reduce non-specific binding

  • Use tissue-specific blocking agents (e.g., brain powder in blocking buffer)

• Isoform considerations:

  • Isoform 1 is highly expressed in brain tissue

  • Select antibodies validated for brain tissue and the specific isoform of interest

• Blood-brain barrier studies:

  • SLC11A2 is a major transporter of manganese across the blood-brain barrier

  • Consider co-staining with endothelial markers for barrier localization studies

How can I optimize SLC11A2 detection in intestinal samples?

Intestinal tissue has high SLC11A2 expression but presents unique challenges:

• Sample preparation:

  • For Western blot: Scrape mucosa with a razor blade after washing with PSS

  • Place directly into Laemmli buffer, shear with 25-gauge needle

  • Heat at 95°C for 6 minutes (higher than standard 60°C for other tissues)

• Localization pattern:

  • SLC11A2 is located on the apical membrane of enterocytes in the digestive tract

  • Look for specific membrane staining pattern in immunohistochemistry

• Function-specific considerations:

  • SLC11A2 carries out H+-coupled transport of divalent metal cations from intestinal lumen

  • For functional studies, consider pH-dependent transport assays

• Isoform expression:

  • Isoforms 3 and 4 are abundantly expressed in duodenum

  • Select antibodies that recognize these isoforms for intestinal studies

What are common problems in SLC11A2 Western blot detection and how can they be resolved?

Common troubleshooting issues for SLC11A2 Western blots:

Additional recommendations:

• For intestinal samples, use specialized extraction protocols as described in search result

• Consider dot blot analysis as an alternative when Western blot proves difficult

• Verify antibody specificity using appropriate positive controls (293T, BxPC-3, SH-SY5Y cells)

How should I address conflicting results between different SLC11A2 antibodies?

When facing conflicting results between different antibodies:

• Epitope mapping:

  • Different antibodies target different regions of SLC11A2

  • N-terminal antibodies may detect different patterns than C-terminal antibodies

• Validation approach:

  • Use multiple antibodies targeting different epitopes

  • Confirm specificity with knockdown/knockout controls

  • Compare results with mRNA expression data (RT-PCR)

• Technical considerations:

  • Different antibodies may require specific optimization for each application

  • Adjust dilution, incubation time, and detection methods based on each antibody's characteristics

• Interpretation guidelines:

  • Consider antibody validation data provided by manufacturers

  • Prioritize results from antibodies with extensive validation in published research

  • Document all experimental conditions when reporting conflicting results

How can SLC11A2 antibodies be used in neurodegenerative disease research?

SLC11A2 plays significant roles in neurodegenerative conditions:

• Disease associations:

  • SLC11A2 is implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis

  • It serves as the major transporter of manganese across the blood-brain barrier

• Research applications:

  • Brain region expression analysis: Map SLC11A2 expression across affected brain regions

  • Metal accumulation studies: Correlate SLC11A2 expression with metal deposition in tissues

  • Blood-brain barrier transport: Investigate SLC11A2's role in metal transport to the brain

• Experimental approaches:

  • Co-immunostaining with neuronal/glial markers

  • Quantitative analysis of SLC11A2 expression in disease models

  • In vitro studies using neuronal cell lines with modified SLC11A2 expression

• Therapeutic implications:

  • SLC11A2 represents a potential target for regulating metal ion transport

  • Antibodies can help validate the effects of SLC11A2-targeting compounds

What methods are recommended for studying SLC11A2 in mitochondrial iron transport?

Recent research suggests SLC11A2 enables Fe(2+) and Mn(2+) entry into mitochondria:

• Subcellular fractionation:

  • Isolate mitochondria using differential centrifugation

  • Verify fraction purity with mitochondrial markers (e.g., VDAC, cytochrome c)

• Co-localization studies:

  • Use confocal microscopy with mitochondrial dyes (MitoTracker)

  • Perform immunofluorescence with SLC11A2 antibodies and mitochondrial markers

• Functional assays:

  • Measure mitochondrial iron uptake in SLC11A2-modulated cells

  • Assess impacts on mitochondrial heme synthesis and iron-sulfur cluster biogenesis

• Experimental design considerations:

  • Compare SLC11A2 localization under normal vs. iron-deficient conditions

  • Assess mitochondrial function parameters in conjunction with SLC11A2 expression

  • Use specific inhibitors to distinguish SLC11A2-mediated transport from other pathways